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Activation of the brain renin-angiotensin system
(RAS) stimulates energy expenditure through in-
creasing of the resting metabolic rate (RMR), and
this effect requires simultaneous suppression of the
circulating and/or adipose RAS. To identify the
mechanism by which the peripheral RAS opposes
RMR control by the brain RAS, we examined mice
with transgenic activation of the brain RAS (sRA
mice). sRA mice exhibit increased RMR through
increased energy flux in the inguinal adipose tissue,
and this effect is attenuated by angiotensin II type 2
receptor (AT2) activation. AT2 activation in inguinal
adipocytes opposes norepinephrine-induced un-
coupling protein-1 (UCP1) production and aspects
of cellular respiration, but not lipolysis. AT2 activation
also opposes inguinal adipocyte function and differ-
entiation responses to epidermal growth factor
(EGF). These results highlight a major, multifaceted
role for AT2 within inguinal adipocytes in the control
of RMR. The AT2 receptor may therefore contribute
to body fat distribution and adipose depot-specific
effects upon cardio-metabolic health.
INTRODUCTION
The renin-angiotensin system (RAS) is well recognized for its var-
ied roles in cardiovascular physiology. Increasing evidence also
supports tissue-specific actions of angiotensin II (ANG) in the
control of energy balance. Human obesity is associated with
increased activity of the circulating RAS (Engeli et al., 2005),
and various studies have documented beneficial effects of
RAS inhibition upon glycemic control endpoints in obese hu-
mans (Grassi et al., 2003; Hsueh et al., 2010; Lindholm et al.,1548 Cell Reports 16, 1548–1560, August 9, 2016 ª 2016 The Author
This is an open access article under the CC BY license (http://creative2003; Shimabukuro et al., 2007). In rodent models, pharmaco-
logical or genetic interference with the RAS also generally has
beneficial effects upon body mass (as reviewed recently [Claflin
and Grobe, 2015; Littlejohn and Grobe, 2015]). It is therefore
confusing that RAS blockade does not have an overt effect
upon body mass in humans. We hypothesize that the multifac-
eted contribution of the RAS to energy balance (through
opposing effects on intake and activity behaviors, digestive effi-
ciency, and resting metabolic rate [RMR]) may result in a net
caloric balance in humans and thereby no change in body
mass. Understanding the tissue-specific molecular mechanisms
by which the RAS mediates control of individual components of
energy balance, such as RMR, will allow for the development of
novel therapeutics for obesity and its sequelae.
While RAS-mediated mechanisms controlling food intake,
digestive efficiency, and physical activity have been defined,
RMR control by the RAS is much more complicated with tissue-
and receptor-specific actions of ANG functioning in apparent
opposition (Claflin and Grobe, 2015; Grobe et al., 2013). Stimu-
lation of the brain RAS by transgenic activation, intracerebro-
ventricular (ICV) infusion of ANG, or deoxycorticosterone
acetate (DOCA)-salt treatment increase RMR through brain
AT1-dependent mechanisms (de Kloet et al., 2011, 2013; Grobe
et al., 2010, 2011; Porter et al., 2003; Porter and Potratz, 2004).
Oddly, chronic infusion of ANG in the periphery can reverse
these effects of a stimulated brain RAS (Grobe et al., 2010),
highlighting the opposing effects of the brain and peripheral ver-
sions of the RAS in energy homeostasis (Grobe et al., 2013).
Thus, there remains a critical lack of understanding of the mech-
anisms that mediate control of RMR by the RAS and, in partic-
ular, how the brain RAS and peripheral RAS interact in this
control. We hypothesize that while ANG acts within the brain
to stimulate RMR, actions of ANG in the periphery suppress
this mechanism of energy expenditure. The objective of the cur-
rent project was therefore to clarify the mechanisms by which
the peripheral RAS opposes the RMR-stimulating effects of
the brain RAS.(s).
commons.org/licenses/by/4.0/).
Figure 1. sRA Mice Exhibit Increased RMR Mediated by Inguinal White Adipose Tissue
(A–D) Body weight (A), food intake (B), activity (C), and heat production (D) asmeasured by respirometry in control and sRAmice (N = 8 per group; four males, four
females).
(E) UCP1 mRNA in BAT, iWAT, skeletal muscle (gastrocnemius), and eWAT (N = 3).
(F) UCP2 mRNA in BAT and iWAT (N = 3).
(G) UCP3 mRNA in BAT, iWAT, skeletal muscle, and eWAT (N = 3).
(H) BAT glucose uptake in control (N = 8; four males, four females) and sRA (N = 7; three males, four females).
(I) iWAT glucose uptake in control (N = 8; four males, four females) and sRA (N = 7; three males, four females).
*p < 0.05 was considered significant. All data presented as mean ± SEM. See also Figure S1.RESULTS
The Brain RAS Stimulates RMR
Double-transgenic ‘‘sRA’’ mice exhibit brain-specific elevations
in RAS activity due to transgenic expression of both a human
renin transgene via the synapsin promoter (sR) and a human an-
giotensinogen transgene under transcriptional control by its own
promoter (A) (Sakai et al., 2007). Under baseline conditions, dou-
ble-transgenic sRA mice exhibit decreased body weight and
proportional fat mass compared to single- and non-transgenic
littermate controls (Figure 1A; Table S1). Although these animals
display normal food intake (Figure 1B) and physical activity (Fig-
ure 1C), sRA mice exhibit an elevated metabolic rate throughout
the light-dark cycle (Figure 1D). These data confirm our previous
studies of elevated energy expenditure in the sRA mouse model(Grobe et al., 2010, 2013) and those of our group and others
studying pharmacological models of elevated brain RAS activity,
including mice and rats with ICV infusion of ANG or DOCA-salt
treatment (de Kloet et al., 2011; Grobe et al., 2011; Hilzendeger
et al., 2013; Porter et al., 2003; Porter and Potratz, 2004). Collec-
tively, these findings support a major stimulatory effect of the
brain RAS upon RMR and thereby energy expenditure.
Selective Modulation of Inguinal Fat Function
We previously established that sRA mice exhibit increased ther-
mogenesis as measured by core body temperature, adipose
sympathetic nerve activity, and RMR when measured at
thermoneutrality (Grobe et al., 2010). To identify the thermogenic
tissue responsible for the increased RMR of sRA mice, we
measured uncoupling protein-1 (UCP1) mRNA, which mediatesCell Reports 16, 1548–1560, August 9, 2016 1549
non-shivering thermogenesis in a variety of tissues (Shabalina
et al., 2013). sRAmice demonstrated a significant (500-fold) in-
crease in UCP1 mRNA specifically within the inguinal white adi-
pose tissue (iWAT); however, there was no change in UCP1
expression between sRA and control mice in interscapular
brown adipose tissue (BAT), skeletal muscle, and epididymal
fat (eWAT) (Figure 1E). We also examined the expression profile
of UCP2, which has low expression in various tissues, andUCP3,
which is more predominant in skeletal muscle and BAT (Vidal-
Puig et al., 1997). The expression of UCP2 was not different be-
tween control and sRA mice in BAT, but was elevated in iWAT of
sRA mice (Figure 1F). UCP3 expression was not changed be-
tween genotypes in BAT, iWAT, skeletal muscle, or eWAT (Fig-
ure 1G). These data point to the inguinal fat as the likely mediator
of the elevated RMR in sRA mice.
Acknowledging that UCP1 mRNA or protein levels do not
equate to energy flux or heat production (Nedergaard and Can-
non, 2013), we next examined rates of glucose uptake in various
tissues as a more direct assessment of energy flux. To analyze
glucose uptake in tissues from control and sRA mice, we per-
formed a glucose tracer test by injecting radiolabeled glucose
([3H]2-deoxyglucose in 20% glucose solution). Glucose uptake
in BAT (Figure 1H), heart (Figure S1A), and quadriceps skeletal
muscle (Figure S1B) were not significantly different in sRA mice
compared to control mice, though a trend toward a possible in-
crease in BAT was noted. In contrast, and complementing the
above UCP1 gene expression data, iWAT exhibited a tremen-
dous, 9-fold, increase in glucose uptake in sRA mice compared
to littermate controls (Figure 1I). Thus, the elevated UCP1
expression in the inguinal fat is associatedwith an increase in en-
ergy flux specifically in this fat depot.
AT2 Activation Suppresses Metabolic Rate
Previously we determined that the suppressed activity of the
circulating RAS in sRA mice is essential for the increased RMR
in these animals. Specifically, we found that chronic peripheral
infusion of a low, non-pressor dose of ANG via subcutaneous
minipump normalized the elevated RMR in these mice without
effect in littermate controls (Grobe et al., 2010). The tissue and
receptor type mediating this action of the exogenous ANG, how-
ever, remained unclear. To examine whether this effect was
directly mediated through actions upon adipocytes or indirectly
mediated through actions upon other tissues, and to identify
the specific receptors that mediate this effect, we next examined
the effects of ANG action in cultured adipocytes.
Blockade of the AT1 receptor with losartan in differentiated
3T3-L1 adipocytes failed to alter UCP1 mRNA (Figure 2A). In
contrast, antagonism of AT2 with PD-123,319 appeared to in-
crease UCP1 expression and low-dose activation of AT2 with
CGP-42112a (‘‘CGP,’’ at doseswhere CGPmaintains AT2-selec-
tivity [Hines et al., 2001] significantly suppressed UCP1
expression (Figure 2A). We confirmed the reduction of UCP1
expression following AT2 activation by CGP treatment (10 nM)
in differentiated primary adipocytes isolated from iWAT of
neonatal wild-type C57BL/6J mice (Figure 2B). Collectively,
these data support a direct, suppressive effect of adipocyte
AT2 receptors upon UCP1mRNA. Given our in vivo data demon-
strating a suppressive role for circulating ANG upon RMR in sRA1550 Cell Reports 16, 1548–1560, August 9, 2016mice (Grobe et al., 2010), we therefore hypothesized that selec-
tive activation of AT2 receptors in sRA mice should normalize
RMR and weight gain in these animals.
Control and sRA mice were chronically infused with saline or
low-dose CGP (50 ng/kg/min, 8 weeks, s.c. [subcutaneously])
to test whether AT2 activation is sufficient to normalize metabolic
function in sRA mice. CGP infusion significantly increased sRA
body mass (Figure 2C) without altering feeding behavior (Fig-
ure 2D). Caloric absorption through the gastrointestinal tract,
as determined by bomb calorimetry, was also not different be-
tween sRA and littermatemice orwithCGP treatment (Figure 2E),
which was consistent with unaltered pancreatic lipase and coli-
pase expression (Figure S2A). We concluded that AT2 activation
did not alter energy intake/uptake, but rather inhibited energy
expenditure.
While chronic AT2 activation had no effect on energy intake,
this manipulation significantly reduced RMR in sRA mice (Fig-
ure 2F), consistent with a suppression of energy expenditure.
Despite no change in the iWAT mass with CGP treatment (Table
S2), the elevated UCP1 expression in this fat padwas normalized
with CGP treatment in sRAmice (Figure 2G). Conversely, despite
a reduction in whole-body RMR, CGP increased UCP1 mRNA in
BAT (Figure S2B), further supporting a dominant role for inguinal
fat in the observed energy balance changes of sRAmice. In addi-
tion to UCP1, the expression of brown or beige adipose markers
(Wu et al., 2012) Cidea (Figure 2H) and Eva1 (Figure 2I) were
normalized in iWAT from sRA mice treated with CGP supporting
further the concept that AT2 activation reversed a ‘‘browning’’ of
the iWAT in sRA mice. Interestingly, despite an increase in PGC-
1a mRNA in iWAT of sRA mice, CGP did not alter PGC-1a
expression (Figure 2J). In addition, analysis of brown or beige
fat markers identified altered Slc27a1, Sp100, Ear2, Tmem26,
Cd40, Hspb7, Acot2, andOplah in the iWAT of sRA mice relative
to control littermate mice, whereas Ear2, Tbx1, Acot2, and Pdk4
were significantly changed with CGP (Figures S2C and S2D;
Table S3). CGP did not have any significant effect upon any
markers in wild-type control mice (Figures 2G–2J). Finally, with
the exception of dermatopontin expression, which was sup-
pressed in sRA mice and stimulated with CGP treatment,
white adipose markers were largely unchanged in sRA mice
(Table S4). These data support the concept that chronic AT2
activation reduces RMR, likely through modulation of the
molecular identity and thereby thermogenic program of the
inguinal fat pad (iWA). Notably these findings do not exclude
the possibility that CGP treatment may also modulate physical-
activity-based energy expenditure; however, other studies
have demonstrated small and opposing effects of AT2 receptor
modulation upon locomotor activity, reducing the likelihood of
a major contribution of this mechanism to the energy balance
changes noted herein (Gross et al., 2000; Hein et al., 1995;
Watanabe et al., 1999). To further understand the mechanism
of the RMR effects, we next investigated possible metabolic tar-
gets of AT2.
AT2 Modulation of RMR Is Not Mediated through
Suppression of Sympathetic Nerve Activity
Sympathetic nerve activity (SNA) is known to mediate adaptive
thermogenesis and thereby contribute to resting metabolism.
Figure 2. Chronic AT2 Activation Reverses Metabolic Phenotypes of sRA Mice
(A) UCP1 mRNA from differentiated 3T3-L1 adipocytes treated with vehicle, losartan (10 mM), PD-123,319 (10 mM), or CGP-42112a ‘‘CGP’’ for 6 hr (N = 3 per
treatment).
(B) UCP1 mRNA in mouse primary adipocytes isolated from iWAT in control mice treated with vehicle (N = 7) or CGP (10 nM; N = 7) for 6 hr.
(C–F) Body mass (C), daily food intake (D), calories absorbed via the gastrointestinal track (E), and oxygen consumption at thermoneutrality (F) in control and sRA
mice treated with saline or CGP. Con+Sal, N = 5 (three males, two females); sRA+Sal, N = 5 (two males, three females); Con+CGP, N = 7 (four males, three
females); sRA+CGP, N = 7 (four males, three females).
(G) UCP1 mRNA in the iWAT (N = 6).
(H) Cidea mRNA in the iWAT (N = 6).
(I) Eva1 mRNA in the iWAT (N = 6).
(J) PGC-1a mRNA in the iWAT (N = 6).
*p < 0.05 was considered significant. All data presented as mean ± SEM. See also Figures S2 and Tables S1 and S2.Therefore, we hypothesized that AT2 activationmay reduce RMR
through suppression of SNA. To test this, we recorded inguinal
sympathetic nerve activity in littermate control or sRA mice
following treatment with saline or the AT2 agonist, CGP (Fig-
ure 3A). SNA to the iWAT was increased in sRA mice compared
to littermate controls (Figures 3B and S3A). This is consistent
with generalized increase in sympathetic activity as we previ-
ously documented, where renal and BAT SNA were elevated in
sRA mice (Grobe et al., 2010). Somewhat unexpectedly, givenits known suppressive functions within the central nervous sys-
tem (Gao and Zucker, 2011), AT2 activation via CGP infusion
failed to reduce SNA in either genotype (Figures 3B and
S3A). Additionally, we determined that while sRA mice exhibit
various changes in blood pressure, heart rate, and renal renin
expression, these endpoints were not significantly affected by
CGP treatment in both control and sRA mice, possibly due
to the low dose of CGP that was administered (Figures S3B
and S3C).Cell Reports 16, 1548–1560, August 9, 2016 1551
Figure 3. AT2 Activation Does Not Reduce Inguinal SNA
(A) Representative electrograms from inguinal sympathetic nerves.
(B) Quantification of thresholded spike count. Con+Sal, N = 10 (three males,
seven females); sRA+Sal, N = 10 (three males, seven females); Con+CGP,
N = 8 each (two males, six females); sRA+CGP, N = 8 each (two males, six
females).
(C) cAMP levels from iWAT isolated from control and sRA mice treated with
saline or CGP (N = 3 per group).
*p < 0.05 was considered significant. All data presented as mean ± SEM. See
also Figure S3.Although the sympathetic drive to the iWAT was not sup-
pressedwith AT2 activation, we next examinedwhether b-adren-
ergic signaling was altered within the iWAT. Therefore, we
measured cAMP, which is produced upon b-adrenergic stimula-
tion, within the iWAT. sRA mice exhibited elevated cAMP in the
iWA, and cAMP levels remain high after AT2 activation (Fig-
ure 3C). Hence, AT2 activation does not reduce SNA or the im-
mediate downstream signal of b-adrenergic stimulation within
inguinal adipose. Rather, AT2 likely may modulate other intracel-
lular signal downstream of cAMP to suppress UCP1 transcrip-
tion, glucose flux, and RMR within the iWAT.
AT2Receptor ActivationBlunts Induction of UCP1mRNA
in White Adipocytes
To further investigate the mechanism of RMRmodulation by AT2
and to determine the effects of direct adipocyte-specific activa-
tion of AT2, we examined second-messenger pathway functions
in cultured primary adipocytes. Adipocytes from the iWA or the
interscapular fat pad (BA) were isolated from neonatal wild-
type C57BL/6J mice and cultured as reported previously (Mar-
kan et al., 2014). To examine the effect of activating AT2 upon
b-adrenergic signaling, we first assessed cAMP production in1552 Cell Reports 16, 1548–1560, August 9, 2016response to norepinephrine (NE; 10 mM) with or without CGP
(10 nM) co-treatment. NE increased cAMP as expected in iWA,
and CGP did not alter this effect (Figure 4A), which was consis-
tent with our in vivo findings (Figure 3C). NE is also known to
induce lipolysis, and liberated fatty acids are required to func-
tionally activate UCP1 protein and to stimulate heat production
(Atgie´ et al., 1997). Therefore, we considered the possibility
that AT2may suppress lipolysis, ultimately suppressing heat pro-
duction. Glycerol levels in the media of the cells were increased
with NE treatment, but not altered with CGP in mouse iWA (Fig-
ure 4B) or BA (Figure S4A). We conclude that AT2 does not
modulate adipocyte cAMP production or lipolysis in response
to NE.
Although lipolysis (and by extension UCP1 ‘‘activity’’) is not
modulated by AT2 activation, our data above support the modu-
lation of UCP1 mRNA expression by AT2 receptors. Activation
of AT2 did not alter NE-induced UCP1 mRNA in cultured
mouse BA (Figure S4B). In contrast, the induction of UCP1
mRNA by NE was significantly blunted with CGP treatment in
mouse iWA (Figure 4C). In a third adipose cell culture model con-
sisting of immortalized human subcutaneous preadipocytes
(Gadupudi et al., 2015; Vu et al., 2013, 2015), we confirmed a
suppressive effect of AT2 activation upon UCP1 mRNA (Fig-
ure 4D). These data support an action of AT2 receptors to modu-
late b-adrenergic signaling downstream of cAMP production
and the bifurcation of second-messenger modulation of UCP1
expression versus lipolysis. AT2 is known to activate the
serine/threonine phosphatase type 2A (PP2A) in other cell types
(Shenoy et al., 1999), which led us to hypothesize that the modu-
latory effect of AT2 activation in adipocytes may be mediated
through phosphatase activity. Consistent with this possibility,
we found that phosphatase inhibition with okadaic acid (OA)
reversed the blunting effect of CGP on NE-induced UCP1
expression (Figure 4C). OA inhibits several phosphatases
including PP1, PP2A, PP4, PP5, and PP6 (Swingle et al., 2007),
and all of these were expressed at detectable levels in our
RNaseq analysis of iWAs (Table S5). Similarly, the AT2 antago-
nist, PD-123,319 (PD), also reversed the effects of AT2 activation
(Figure 4C). Together these data confirm the AT2-dependent
action of CGP in adipocytes to specifically modulate UCP1
expression (not activation) and implicate the activation of an
OA-dependent phosphatase in this mechanism.
cAMP-response element binding protein (CREB) induces
UCP1 transcription in response to elevated cAMP signaling
(Rim and Kozak, 2002). Examination of known CREB target
genes in the iWAT transcriptome via RNA sequencing (RNaseq)
uncovered that 15 CREB targets had altered expression levels in
control versus sRA mice and that the expression patterns of 7 of
these genes were then significantly reversedwith CGP treatment
(Figure 4E; Table S6). CREB phosphorylation at Ser133 was
increased after NE treatment and significantly attenuated with
CGP co-treatment in mouse iWA (Figure 4F). Finally, antagonism
of AT2 activation by PD-123,319 disinhibited CREB binding to
theUCP1 promoter in differentiated 3T3-L1 adipocytes in a chro-
matin immunoprecipitation assay (Figure 4G). Therefore, AT2
likely blocks transcription of UCP1 through the phosphatase-
mediated dephosphorylation and subsequent inactivation of
the CREB transcription factor.
Figure 4. AT2 Activation Suppresses
Norepinephrine Induced UCP1 in White Ad-
ipocytes
(A) cAMP levels from mouse white adipocytes
from iWAT (iWA) following treatment for 6 hr with
vehicle, NE (10 mM), or NE andCGP (10 nM) (N = 6).
(B) Glycerol in the media from mouse iWA
following treatment for 6 hr with vehicle, NE, or NE
and CGP (N = 6).
(C) UCP1 mRNA in mouse iWA treatment for 6 hr
(N = 7–8).
(D) UCP1 mRNA in human immortalized adipo-
cytes following treatment for 6 hr with vehicle
(N = 16), CGP (N = 11), NE (N = 9), or NE and CGP
(N = 11).
(E) Expression of CREB target genes in iWAT
transcriptome dataset.
(F) Representative western blot and quantification
of western blot analysis of total and phosphory-
lated CREB in mouse iWA treated with vehicle, NE
(1 mM), or NE + CGP (10 nM; N = 5 per group) for
5 min. b-actin served as a loading control.
(G) Chromatin immunoprecipitation assay for
binding of CREB to the UCP1 promoter with CGP
(10 nM) ± PD (10 mM); N = 3.
*p < 0.05 was considered significant. All data
presented asmean ±SEM. See also Figure S4 and
Table S3.AT2 Activation Does Not Decrease Canonical Natriuretic
Peptide Signaling
Positive implication of an AT2/phosphatase/CREB mechanism
does not rule out other potential contributors to elevated RMR
in sRA mice or other potential targets of AT2 signaling in iWA.
To probe these other potential mechanisms, we considered
natriuretic peptide signaling, which has been reported to in-
crease RMR and induce UCP1 in mice (Bordicchia et al.,
2012). Upon atrial natriuretic peptide (ANP) or brain natriuretic
peptide (BNP) binding to the signaling receptor, NPR-A, intracel-
lular cGMP is produced. cGMP levels have been shown to be
altered by AT2 in other cell types (Bottari et al., 1992), raising
the possibility that adipose natriuretic peptide signaling may be
modulated by AT2 signaling. Furthermore, chronic hypertension
(as previously documented in sRA mice [Grobe et al., 2010; Lit-
tlejohn et al., 2013; Sakai et al., 2007]) has been correlated with
increased levels of ANP (Sagnella et al., 1986) and BNP (Kohno
et al., 1992). Thus, we assessed whether natriuretic peptide
signaling is increased in sRA mice, and this may contribute to
elevated RMR.
Total daily loss of ANP to urine (Figure 5A) was elevated in sRA
mice even though no change in plasma ANP was detected (Fig-
ure S5A), supportive of an increased total daily ANP release. To
determine if sensitivity to natriuretic peptide in iWATwas altered,Cell Rewe measured the expression of the ca-
nonical signaling receptor, NPR-A, and
the clearance receptor, NPR-C. While
NPR-A expression (Figure 5B) was not
different, saline-treated sRA mice have
decreased NPR-C mRNA (Figure 5C)
compared to control mice. An enhancedsignaling-to-clearance receptor mRNA ratio was proposed to
indicate elevated sensitivity to natriuretic peptide signaling (Bor-
dicchia et al., 2012). Therefore, the increased ratio of these re-
ceptor transcripts in iWAT of sRA mice (Figure 5D) may indicate
greater sensitivity to natriuretic peptide signaling in sRA mice.
CGP increased the expression of NPR-C and normalized the re-
ceptor ratio in sRA iWAT. As expected, iWAT cGMP levels were
elevated in sRAmice, but surprisingly CGP did not reduce cGMP
(Figure 5E). Thus, even though natriuretic peptide signaling ap-
pears to be enhanced in sRA iWAT and AT2 activation increased
the expression of the NPR-C clearance receptor, AT2 activation
does not suppress immediate second-messenger activation due
to natriuretic peptide signaling. Therefore, the NPR-A/cGMP
pathway is unlikely to mediate the observed effects of AT2 acti-
vation upon UCP1 and RMR.
AT2 Activation Reduces RMR via Suppression of Growth
Factor Signaling
Next, we used an unbiased approach to identify additional
signaling pathways that are altered in the iWAT of sRA mice.
Specifically, we analyzed the transcriptome of iWAT from control
and sRA mice treated with either saline or CGP, using RNA
sequencing. From this examination, 123 genes were identified
as having significantly altered expression (p < 0.001) betweenports 16, 1548–1560, August 9, 2016 1553
Figure 5. AT2 Activation Does Not Suppress
Canonical Natriuretic Peptide Signaling
(A) Urine ANP levels (N = 6; three males, three
females).
(B) NPR-A mRNA in iWAT N = 4 per group (two
males, two females).
(C) NPR-C mRNA in iWAT N = 4 per group (two
males, two females).
(D) NPR-A to NPR-CmRNA ratio in iWAT N = 4 per
group (two males, two females).
(E) cGMP levels in iWAT (N = 4; two males, two
females).
*p < 0.05 was considered significant. All data
presented as mean ± SEM. See also Figure S5.control and sRA mice. Intriguingly, the alterations in expression
of these same 123 genes were largely reversed with CGP treat-
ment (Figure 6A). Gene set enrichment analysis (GSEA) (Subra-
manian et al., 2005) of the dataset uncovered that genes in the
epidermal growth factor (EGF) signaling pathway were, as a
group, upregulated (p value = 0.02) in sRA mice compared to
littermate controls and suppressed (p value = 0.02) by CGP treat-
ment. These data precipitated the hypothesis that AT2 may addi-
tionally modulate RMR in sRA mice via interference with EGF
signaling within the iWA.
To test if AT2 targets EGF signaling to modulate RMR
in vivo, we chronically infused wild-type C57BL/6J male
mice for 2 weeks with saline, EGF (0.833 mg/hr, s.c.), CGP
(50 ng/kg/min, s.c.), or both EGF and CGP. There was no signif-
icant change in bodymass (Figure 6B), food intake (Figure 6C), or
gastrointestinal caloric absorption (Figure 6D) in any treatment
group during this relatively short-term treatment. In contrast,
fat mass was reduced with EGF treatment, and this corre-
sponded with an increase in lean body mass (Table S7). Criti-
cally, CGP co-treatment with EGF significantly reduced heat
production compared to EGF alone (Figure 6E), though this co-
treatment did not significantly alter the effect of 2-week EGF
treatment upon adipose mass (Table S7). Therefore, AT2 activa-
tion in wild-type mice is sufficient to reduce EGF-induced heat
production.
To further examine the effects ofAT2modulationuponRMRand
the interaction between AT2 and EGF in the control of RMR, we
examined RMRcontrol inmice genetically deficient for the AT2 re-
ceptor (AT2-KO), originally developed by Drs. Victor J. Dzau and
RichardE.Pratt (Heinetal., 1995).Micedeficient for theAT2 recep-
tor, originally on the FVB/NCrl genetic background, were back-1554 Cell Reports 16, 1548–1560, August 9, 2016crossed onto the C57BL/6J background
for > 7 generations before testing. RMR
in a cohort of five male AT2-KO (29.32 ±
1.62 g) and five weight-matched male
littermate control mice (28.75 ± 1.52 g)
was examined by respirometry. Although
nochangewasobserved in respiratory ex-
change ratio (RER; control 0.832 ± 0.010,
AT2-KO 0.833 ± 0.012), AT2-KO mice ex-
hibited a robust increase in RMR (control
0.217 ± 0.006 versus AT2-KO 0.272 ±
0.019 kcal/hr, p = 0.02) (Figure S6).We next tested the RMR responses of AT2-KOmice and litter-
mate controls to 2-week subcutaneous infusion of EGF. Body
mass increased after EGF infusion in both littermate control
(4.98 ± 0.36 g) and AT2-KO (5.63 ± 0.35 g) mice compared to
baseline, but this weight gain was reduced compared to un-
treated age-matched control and AT2-KO mice (Figure 6F).
Food intake (Figure 6G) and total caloric absorption (Figure 6H)
were unchanged by treatment or genotype. EGF reduced iWAT
and eWAT mass (Table S8), which is consistent with decreased
adiposemass in EGF-treated rats (Pedersen et al., 2000; Serrero
and Mills, 1991). Because of the wide differences in body
weights between groups, we normalized heat production using
analysis of covariance (ANCOVA) adjustment. As above, un-
treated AT2-KO mice exhibited increased heat production
compared to littermate controls under baseline conditions,
consistent with a tonic inhibitory role for AT2 in RMR control (Fig-
ure 6I). In addition, EGF increased heat production in both geno-
types, but increased RMR in AT2-KOmice to a much higher level
than in littermate controls (Figure 6I). Therefore, we conclude
that AT2 receptors act as tonic suppressors of RMR, and this
is related to alterations in EGF signaling.
Surprisingly, the mechanism of interaction between AT2 and
EGF in the adipose appears to be independent of modulation
of UCP1 mRNA. UCP1 mRNA in the iWAT pad was unchanged
(Figure S7A) or reduced (Figure S7B) by EGF infusion. In addi-
tion, we determined that UCP1 mRNA was unchanged by EGF
treatment with or without co-treatment with the AT2 antagonist,
PD-123,319, in cultured adipocytes (Figure S7C), similar to our
in vivo observations. In contrast, the effects of EGF upon adipo-
cytes have largely been attributed to the modulation of differen-
tiation (Hauner et al., 1995; Lee et al., 2008; Serrero, 1987). Thus,
Figure 6. AT2 Activation Suppresses EGF Signaling In Vivo
(A) Genes identified through RNA sequencing analysis from the iWAT isolated from control or sRAmice treated with saline or CGP. Top: includes genes known to
be associated with EGF signaling. Bottom: genes not associated with EGF.
(B–E) Body mass (B), daily food intake (C), calories absorbed via the gastrointestinal tract (D), and heat as measured by respirometry (E) in wild-type C57BL/6J
male mice treated for 2 weeks with saline (N = 20), EGF (N = 20), CGP (N = 9), or EGF and CGP (N = 17).
(F–I) Body mass (F), food intake (G), calories absorbed via the gastrointestinal track (H), or ANCOVA-adjusted heat production (I) in control and AT2-KO mice (all
males) at baseline, age-matched untreated control mice (N = 11), untreated AT2-KO mice (N = 12), or after 2-week EGF treatment in control mice (N = 4) and
AT2-KO mice (N = 4).
*p < 0.05 was considered significant. All data presented as mean ± SEM. See also Figure S6 and Tables S4 and S5.
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Figure 7. AT2 Activation Reverses the Sup-
pressed Adipogenesis by EGF
(A) Representative image of oil red O staining on
day 4 of differentiation in mouse iWA treated with
or without EGF (1 ng/mL) and/or CGP (10 or
100 nM). Scale bar, 1 mm.
(B) Quantification of oil red O staining (N = 5 per
group).
(C) Oxygen consumption rate (OCR) in primary
mouse WA treated with vehicle (N = 20), EGF
(N = 10), or EGF and CGP (N = 20) during differ-
entiation. Cells were subjected to a mitochondria
stress test by acute stimulation with oligomycin,
FCCP, and Antimycin A/Rotenone. WC, white
adipocyte.
(D) Expression of electron transport genes identi-
fied as an enrichment set by GSEA in iWAT tran-
scriptome-dataset.
(E) Model of elevated brain RAS and subsequent
suppressed circulating RAS induction of resting
metabolism.
*p < 0.05 was considered significant. All data
presented as mean ± SEM. See also Table S6.we examined the modulatory effect of CGP upon adipocyte dif-
ferentiation. EGF treatment during differentiation resulted in a
major suppression of adipocyte oil red O staining (Figure 7A).
Consistent with the results above, CGP dose-dependently
blunted the inhibitory effect of EGF on adipocyte differentiation
(Figure 7B). To determine the functional significance of EGF-
altered adipocyte differentiation, we measured oxygen con-
sumption rate (OCR; normalized to cell number) in cells
supplemented with EGF and/or CGP during differentiation (Fig-
ure 7C). Though EGF treatment had no significant effects upon
basal OCR, CGP treatment significantly (main effect p = 0.04)
suppressed basal OCR. Oligomycin treatment revealed a signif-
icant effect of CGP (main effect p < 0.01) to reduce proton leak
consistent with a suppressive effect upon UCP1 expression in1556 Cell Reports 16, 1548–1560, August 9, 2016these cells. This major suppression of un-
coupled proton leak by CGP (CGP alone
was 62% of vehicle, and EGF+CGP was
46% of EGF alone) is consistent with the
suppressive effect of CGP upon UCP1
and RMR in vivo (Figures 2F, 2G, 6E,
and 6I). In addition, EGF increased ATP
turnover by 32% in the absence of CGP
(EGF3CGP interaction p = 0.03), consis-
tent with a cross-talk between EGF and
AT2 in the control of electron transport
chain activity. GSEA of the iWAT tran-
scriptome from control and sRA mice
treated with and without CGP (as pre-
sented in Figure 6A) uncovered a signifi-
cant change in the expression of electron
transport chain components (Figure 7D;
Table S6). In the absence of CGP, EGF
significantly increased maximal OCR re-
sponses to carbonyl cyanide-4-phenyl-
hydrazone (FCCP) by 19% compared tovehicle, also supporting a major modulatory effect of EGF
upon adipocyte thermogenic capacity. These data confirmphys-
iologically significant and direct actions of both EGF and AT2
within the inguinal adipocyte to modulate energy turnover and
highlight complex interactions that may represent novel thera-
peutic targets for controlling adipocyte identity and function.
DISCUSSION
The implication of the RAS in the control of energy homeostasis
in addition to its well-recognized role in cardiovascular functions
may help clarify the comorbidity of metabolic and cardiovascular
diseases, such as obesity and hypertension. The present study
helps to illuminate the mechanisms involved in metabolic control
by the RAS. Specifically, we have documented actions of AT2
receptor within inguinal adipocytes to control the molecular
identity and thermogenic capacity of these cells (Figure 7E), ulti-
mately to regulate whole-body energy balance. These insights
help to clarify the nuanced and multifaceted effects of ANG in
the periphery in the control of energy expenditure and the mech-
anisms of cross-talk between the brain and peripheral RAS.
Future obesity therapeutics targeting the RAS may take advan-
tage of the selective actions of ANG through the AT2 receptor
or its downstream targets specifically within subcutaneous adi-
pose to modulate RMR and thereby energy homeostasis.
The adipose RAS contributes to obesity-hypertension, and
adipose expansion is responsive to both the local adipose RAS
and the circulating RAS (Goossens et al., 2003; Yvan-Charvet
andQuignard-Boulange´, 2011). For example, transgenic overex-
pression of angiotensinogen specifically in adipose tissue
causes mice to become hypertensive and obese (Yvan-Charvet
et al., 2009). Yiannikouris et al. found that adipose-specific
disruption of angiotensinogen prevents the induction of hyper-
tension, but not weight gain, with diet-induced obesity (Yianni-
kouris et al., 2012a, 2012b). Consistent with these findings and
the current study, Yvan-Charvet et al. previously demonstrated
that genetic disruption of the AT2 receptor prevented obesity
but had no antihypertensive effect in mice overexpressing angio-
tensinogen in adipose tissue (Yvan-Charvet et al., 2005, 2009).
Intriguingly, the actions of AT2 to modulate UCP1 expression
appear to be limited to the inguinal (subcutaneous) adipose
pad. This discovery is interesting both mechanistically and for
its clinical implications. As subcutaneous fat is largely consid-
ered ‘‘beneficial’’ opposed to inflammatory abdominal or visceral
fat (Abate et al., 1995; McLaughlin et al., 2011; Miyazaki and
DeFronzo, 2009), and as obesity is associated with increased
circulating RAS activity (Engeli et al., 2005; Yasue et al., 2010),
these findings implicate the adipose RAS in the modulation of
cardio-metabolic risks during obesity.
The discovery of an interaction between AT2 receptor sig-
naling and EGF receptor signaling within adipocytes was not
entirely unexpected. Others have previously documented a
role for EGF in adipose development, and interactions between
EGF and AT2 have been reported in other tissues (Meffert
et al., 1996; Nouet et al., 2004; Plouffe et al., 2006). Our data indi-
cate that AT2 stimulation impairs oxidative phosphorylation and
highlight an important interaction between EGF and the AT2
within inguinal adipocytes, but the molecular mechanism of
this interaction remains elusive. Increased body mass index is
correlated with a reduction in electron transport chain compo-
nents resulting in decreased OCR in human adipocytes (Fischer
et al., 2015). Thus, one possible mechanism for the elevated
maximal oxidative phosphorylation observed with EGF treat-
ment is an alteration in levels of electron transport chain
components. Although further analysis of these mechanisms is
warranted to determine how EGF and AT2 modulate oxidative
phosphorylation capacity, our data clearly support an interaction
between EGF and the AT2 receptor on adipocytes. Given our
previous demonstration that the AT2 receptor modulates anaer-
obic metabolism in vivo (Burnett and Grobe, 2013) and the pre-
viously established role for EGF in the modulation of anaerobic
metabolism in cancer cells (Lee et al., 2015; Velpula et al.,2013), we posit that the molecular interaction between AT2 and
EGF within adipocytes may prove to be similar to that which oc-
curs in cells exhibiting the Warburg effect. Another possible
contributing mechanism may involve futile cycling of substrates
such as creatinine, as this pathway has recently been docu-
mented as another UCP1-independent pathway of energy
expenditure by adipocytes (Kazak et al., 2015).
Although no sex differences were noted in the current study,
some data support a complex, sex-dependent contribution of
AT2 to the regulation of weight gain. Samuel et al. previously
demonstrated that weight gain of AT2-deficient mice on a
high fat diet is normal in males but accelerated in females
(Samuel et al., 2013). Nag et al. also previously demonstrated
that pharmacological activation of the AT2 receptor with C21
attenuated high-fat-diet-induced weight gain in female mice
(Nag et al., 2015). How AT2 may contribute to sex differences
in susceptibility to weight gain, in terms of physiological mecha-
nism (intake behavior, digestive efficiency, RMR, etc.) or molec-
ular mechanism (activation of phosphatases, interference with
EGFR signaling, etc.) remains unclear. Nonetheless, given the
inguinal-fat-specific role for AT2 action noted herein, a potential
role for AT2 in observed differences in adiposity and patterns
of adipose distribution and adipose function (Blaak, 2001;
Krotkiewski et al., 1983) between males and females could be
speculated.
Ultimately these studies support the general concept that tis-
sue- and receptor-specific actions of the RAS contribute to en-
ergy homeostasis (Littlejohn and Grobe, 2015). This overall
concept likely helps to explain the lack of efficacy of ‘‘global’’
pharmacological RAS inhibition as a therapeutic approach to hu-
man obesity. Human obesity is correlated with increased circu-
lating RAS activity (Engeli et al., 2005; Yasue et al., 2010), which
would be expected to increase SNA (de Kloet et al., 2010). How-
ever, increased circulating RAS activity would presumably stim-
ulate AT2 signaling in thermogenic (or potentially thermogenic)
adipose, resulting in reduced thermogenic capacity and thermo-
genesis in response to SNA stimulation. While pharmacological
inhibition of the peripheral RAS could result in reduced adipose
AT2 activation, the loss of compartmentalization during obesity
due to increased permeability of the blood-brain barrier (Gustaf-
son et al., 2007) would simultaneously result in reduced brain
RAS activation. The net effect on body mass would therefore
be expected to be negligible. Future work to develop selective
AT2 antagonists that are incapable of crossing even a highly
permeable blood-brain barrier may therefore prove useful for
obesity therapeutics.EXPERIMENTAL PROCEDURES
Experimental procedures are outlined in detail in the associated Supplemental
Information.
Animals
All procedures performed were approved by the University of Iowa’s Institu-
tional Animal Care and Use Committee and conform to the guidelines set forth
by the National Research Council (National Research Council, 2011). The sRA
(sRAflox line 11110/2 X 4284/1) transgenic colony was generated as previously
described (Grobe et al., 2010; Sakai et al., 2007). Mice were treated with sub-
cutaneous infusion of saline, CGP-42112a (100 ng/kg/min, s.c.), or EGF (AbDCell Reports 16, 1548–1560, August 9, 2016 1557
Serotec; 0.833 mg/hr, s.c.) using Alzet osmotic minipumps. AT2-KOmice, orig-
inally developed by Victor J. Dzau and Richard E. Pratt (Hein et al., 1995) were
obtained from Charles River Laboratories on the FVB/NCrl background and
were backcrossed onto the C57BL/6J background for at least seven genera-
tions. All animals had ad libitum access to standard chow (Harlan Teklad 7013)
and water and were maintained on a standard 12:12 hr lighting cycle.
In Vivo Glucose Uptake Assay
Tail blood was collected from all mice (time = 0) followed by an injection (intra-
peritoneally [i.p.]) of 8–10 mCi of [3H]-2-deoxyglucose in a 20% glucose solu-
tion. Plasma radioactivity and [3H]-2-deoxyglucose uptake in tissues was
analyzed as previously described (Markan et al., 2014).
Sympathetic Nerve Activity
Sympathetic nerve activity to the iWA was assessed as previously described
(Grobe et al., 2010; Rahmouni et al., 2008).
Primary Adipocyte Culture
iWAT or interscapular BAT was collected from 4-day-old pups as previously
described (Markan et al., 2014).
Immortalized Human Preadipocyte/Adipocyte Culture
Immortalized normal human preadipocytes (NPADs) have been described pre-
viously (Vu et al., 2013).
Cellular Respiration
Mouse primary inguinal white adipocytes were seeded and grown in XF96 V3
PET cell culture microplates (Seahorse Biosciences). OCR values were
normalized to cell numbers as previously described (Wagner et al., 2011).
The final mitochondrial inhibitor concentrations used were 2.5 mM oligomycin,
0.75 mM FCCP, 10 mM rotenone, and 10 mM Antimycin A.
RNA Sequencing Analysis
Total RNA was isolated from the iWA and was used to generate cDNA libraries
with each library tagged with a unique sequence barcode. The libraries were
sequenced (50-bp paired end reads) with the Illumina HiSeq 2000 at the
DNA Facility at Iowa State University. The quality of the sequence reads was
verified using the FastQC program. Bowtie (Langmead et al., 2009) was
used to align sequences to the mouse genome (mm9, NCBI37) with alignment
results saved in binary alignment map/sequence alignment map (BAM/SAM)
format. The SortSam function of Picard Tools was used to sort SAM files
and paired reads not mapping to the same genomic location were removed.
The number of sequence reads per gene was calculated using the count func-
tion of gfold (Feng et al., 2012). The total counts per genewas normalized using
the edgeR (Robinson et al., 2010) package in R/Bioconductor to account for
the variance in the number of total sequence reads between samples. Statis-
tical analysis of differential expression was done using the edgeR (Robinson
et al., 2010), package and p value correction for multiple testing was done us-
ing the qvalue (Storey and Tibshirani, 2003) package in R/Bioconductor. An
adjusted p value less than 0.001 was considered statistically significant.
Statistical Analyses
ANOVA (with or without repeated measures as appropriate) followed by Tukey
multiple comparisons procedures were used throughout, with p < 0.05 consid-
ered statistically significant. ANCOVAwas used to correct data for bodymass,
as indicated. Gene expression data were analyzed using the Livak method (Li-
vak and Schmittgen, 2001). Mann-Whitney U, Kruskal-Wallis, or Friedman’s
ANOVAwere used when data failed normality or equal variance tests, and their
applications are noted in figure legends if used. Data are presented as mean ±
SEM throughout.
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